腫瘤流式細胞技術市場－全球產業規模、佔有率、趨勢、機會和預測：按組件、技術、適應症、應用、最終用戶、地區和競爭格局分類，2021-2031年

全球腫瘤學領域的流式細胞技術市場預計將從 2025 年的 24.1 億美元大幅成長至 2031 年的 39.7 億美元，複合年成長率為 8.67%。

這項技術利用雷射方法分析液體懸浮液中細胞的特性，對於免疫表現型分析、細胞分選和微量殘存疾病檢測等應用至關重要，尤其是在白血病和淋巴瘤的診斷方面。推動該市場成長的主要因素是全球癌症發生率的上升，這導致對精準診斷解決方案的迫切需求。例如，美國癌症研究協會 (AACR) 報告稱，預計到 2025 年，全球將新增 2,000 萬例癌症病例。

從藥物發現到臨床試驗，流式細胞技術在藥物研發領域的廣泛應用進一步推動了該市場的成長。隨著個人化醫療的活性化，實驗室越來越需要採用流式細胞技術等高通量篩檢工具來加速新治療方法的開發。儘管需求強勁，但該行業仍面臨一個重大障礙：安裝和維護流式細胞技術設備需要大量的資金投入。如此高的營運成本可能會阻礙資源匱乏地區的採用，並可能阻礙市場的整體擴張。

市場促進因素

全球血液系統惡性腫瘤和固態腫瘤發生率的不斷上升是流式細胞技術市場的主要驅動力，也因此催生了對能夠精準識別疾病的先進診斷設備的需求。隨著血液系統惡性腫瘤盛行率的不斷攀升，流式細胞技術已成為快速免疫表現型分析和微量殘存疾病（MRD）監測的關鍵技術，並逐漸成為腫瘤學領域的標準檢測手段。該技術能夠為臨床醫生提供詳細的細胞訊息，從而指南治療策略，尤其是在白血病和淋巴瘤等複雜病例中，精準的細胞選擇至關重要。例如，美國癌症協會預測，到2025年，美國將新增約192,070例白血病、淋巴瘤和多發性骨髓瘤病例，如此龐大的患者群體直接推動了對高通量流式細胞技術檢測和穩定試劑的需求，以滿足診斷需求。

此外，製藥和生技領域研發投入的大幅成長正顯著推動市場成長。生物製藥公司在其藥物研發過程中廣泛應用多參數流式細胞技術，以在單細胞層級評估藥物的療效和毒性。這對於開發創新免疫療法和個人化治療至關重要。對創新的大量投入確保了先進流式細胞技術設備的持續應用。例如，百時美施貴寶公司在2024年財務報告中揭露，其年度研發支出為112億美元，凸顯了在治療方法進步方面投入的巨額資金。除了私人資金外，公共部門的支持仍然至關重要，美國國家癌症研究所（NCI）在其2025年預算中撥款72.2億美元，用於加強癌症研究、教育和培訓舉措。

市場挑戰

阻礙全球流式細胞技術市場在腫瘤學領域擴張的主要障礙之一是所需設備的安裝和維護都需要大量的初步投資。流式細胞技術系統由複雜的流體和光學元件組成，需要大量的初始投資，這使得預算有限的小規模診所和學術機構難以採用。持續的營運成本，包括昂貴的試劑、定期維護以及聘請熟練技術人員操作設備，進一步加重了這項經濟負擔。因此，這些高昂的支出常常迫使許多機構推遲設備升級或依賴外部檢測服務，從而有效地限制了新型流式細胞技術儀的普及應用。

這些財政限制對那些醫療預算中治療支出優先於診斷基礎設施投資的地區影響尤為嚴重。因此，這些地區採用先進的流式細胞技術平台的速度明顯滯後。根據社區癌症中心協會2024年的報告，45%的癌症計畫指出，高昂的營運成本和保險報銷困難是擴大服務範圍的主要障礙。這種經濟壓力直接削弱了癌症中心實施高通量篩檢技術的能力，從而阻礙了更廣泛的市場發展。

市場趨勢

頻譜流式細胞技術在高維度表現型分析領域的快速應用，有效克服了傳統補償方法的局限性，正在革新腫瘤學研究。這項創新技術利用全光譜螢光分析來區分頻譜螢光染料的發射光譜，以便同時測量超過40個參數。這項能力對於深入分析複雜的腫瘤微環境至關重要。全球研究機構對此先進儀器的日益普及，凸顯了其在市場上的重要性。正如Cytek Biosciences在2025年11月報告的那樣，該公司在全球的安裝量已達3456台，這清晰地表明了業界正朝著頻譜分析的方向發展。

同時，人工智慧 (AI) 在自動化數據設門和分析中的應用，正在解決高通量腫瘤學工作流程中的一個重大挑戰：「數據解讀瓶頸」。 AI 演算法正逐步整合到分析軟體中，實現細胞群識別的標準化，並最大限度地減少人為操作的不一致。這對於處理現代流式細胞技術資料集的複雜性至關重要。這些技術的融合簡化了以往繁瑣的任務，並顯著提高了操作效率。 2025 年 10 月，《SelectScience》雜誌報道稱，AI 輔助設門工具的引入簡化了工作流程，將分析時間從數小時的手動工作縮短到幾分鐘，從而加快了精準腫瘤學的決策速度。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球流式細胞技術市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依組件分類（檢測試劑盒、儀器、試劑/耗材、軟體）
  • 依技術分類（基於細胞、以微珠為基礎）
  • 適應症（骨髓惡性腫瘤、固體癌）
  • 依應用領域（轉化研究、臨床應用）
  • 依最終使用者（醫院/診所、診斷檢查室、學術/研究機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美腫瘤流式細胞技術市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲腫瘤學流式細胞技術儀市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區腫瘤流式細胞技術市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲腫瘤學流式細胞技術市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲腫瘤流式細胞技術市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球流式細胞技術市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Agilent Technologies, Inc.
• Apogee Flow Systems Ltd.
• Becton, Dickinson and Company
• bioAffinity Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Cytognos, SL
• Danaher Corporation
• Miltenyi Biotec BV & Co. KG
• Laboratory Corporation of America Holdings

第16章 策略建議

第17章：關於研究公司及免責聲明

The global flow cytometry market within oncology is projected to expand significantly, increasing from USD 2.41 Billion in 2025 to USD 3.97 Billion by 2031, demonstrating an 8.67% Compound Annual Growth Rate. This technology, which uses laser-based methods to examine cellular characteristics in a fluid suspension, is vital for applications such as immunophenotyping, cell sorting, and detecting minimal residual disease, especially in the context of leukemia and lymphoma diagnostics. A major impetus behind this market's growth is the rising global incidence of cancer, which generates an urgent demand for accurate diagnostic solutions. For instance, the American Association for Cancer Research reported an estimated 20 million new cancer cases worldwide in 2025.

The market's growth is additionally bolstered by the widespread use of flow cytometry in pharmaceutical research, encompassing both drug discovery and clinical trials. As the pursuit of personalized medicine intensifies, laboratories are increasingly pressured to implement high-throughput screening tools like flow cytometry to expedite the development of new therapies. Despite this robust demand, the industry encounters a substantial hurdle: the considerable capital outlay required for acquiring and maintaining flow cytometry equipment. Such elevated operational expenses pose a barrier to adoption in environments with limited resources, potentially hindering the market's overall expansion.

Market Driver

The increasing global occurrence of both hematological cancers and solid tumors is a key driver for the flow cytometry market, demanding sophisticated diagnostic instruments for precise disease identification. With the growing prevalence of blood cancers, flow cytometry has become indispensable for swift immunophenotyping and monitoring minimal residual disease (MRD), cementing its role as a standard practice in oncology. This technology offers clinicians detailed cellular information essential for guiding treatment strategies, especially in intricate cases of leukemias and lymphomas where accurate cell sorting is crucial. For example, the American Cancer Society projected approximately 192,070 new cases of leukemia, lymphoma, and myeloma in the United States in 2025, indicating a significant patient volume that directly fuels the need for high-throughput cytometric assays and consistent reagents to manage diagnostic demands.

Furthermore, a substantial surge in research and development investments within the pharmaceutical and biotechnology sectors is considerably advancing market growth. Biopharmaceutical firms extensively employ multiparametric flow cytometry in their drug discovery processes to evaluate drug efficacy and toxicity at a single-cell resolution, a critical aspect for developing innovative immunotherapies and personalized treatments. This significant financial dedication to innovation guarantees the ongoing acquisition of advanced flow cytometry instruments. As an illustration, Bristol Myers Squibb reported annual R&D expenditures of $11.2 billion in its 2024 financial results, highlighting the immense capital allocated to therapeutic progress. Beyond private funding, public sector support remains crucial, with the National Cancer Institute allocating $7.22 billion in its fiscal year 2025 budget to bolster cancer research and training initiatives.

Market Challenge

A significant obstacle hindering the expansion of the global flow cytometry in oncology market is the considerable capital outlay needed for both acquiring and maintaining the necessary instrumentation. Flow cytometry systems, composed of intricate fluidic and optical elements, demand a substantial initial investment, making them challenging for smaller clinics and academic institutions with restricted budgets to procure. This financial strain is exacerbated by recurring operational costs, which include expensive reagents, routine servicing, and the necessity for specialized technicians to operate the equipment. Consequently, these high expenditures often compel many facilities to postpone equipment upgrades or resort to external testing services, thereby inherently capping the adoption of new flow cytometry units.

These financial limitations are especially damaging in areas where healthcare budgets prioritize critical treatments over investments in diagnostic infrastructure. As a result, the uptake of sophisticated flow cytometry platforms is markedly slower in such regions. A 2024 report by the Association of Community Cancer Centers indicated that 45 percent of cancer programs identified high operational costs and reimbursement difficulties as major impediments to expanding their service offerings. This economic pressure directly impairs oncology centers' capacity to acquire high-throughput screening technologies, consequently impeding the market's broader development.

Market Trends

The swift integration of spectral flow cytometry for high-dimensional phenotyping is revolutionizing oncology research by effectively addressing the constraints of traditional compensation methods. This innovative technology employs full-spectrum fluorescence analysis to differentiate the emission profiles of fluorochromes that have overlapping spectra, allowing for the simultaneous measurement of more than 40 parameters. This capability is crucial for intricately analyzing the complex tumor microenvironment. The increasing adoption of this advanced instrumentation across research facilities worldwide underscores its growing market significance. As reported by Cytek Biosciences in November 2025, their global installed base reached 3,456 instruments, highlighting the industry's clear move towards spectral analysis for thorough immunoprofiling.

Simultaneously, the incorporation of Artificial Intelligence for automated data gating and analysis is resolving a key challenge in high-throughput oncology workflows: the bottleneck of data interpretation. AI algorithms are progressively being integrated into analysis software to standardize the identification of cell populations and minimize inconsistencies between users, which is vital for handling the intricate nature of contemporary cytometric datasets. This technological fusion significantly enhances operational efficiency by simplifying tasks that were previously labor-intensive. SelectScience reported in October 2025 that the implementation of AI-assisted gating tools has streamlined workflows, cutting analysis times from several hours of manual effort to mere minutes, thereby accelerating decision-making in precision oncology.

Key Market Players

• Agilent Technologies, Inc.
• Apogee Flow Systems Ltd.
• Becton, Dickinson and Company
• bioAffinity Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Cytognos, S.L.
• Danaher Corporation
• Miltenyi Biotec B.V. & Co. KG
• Laboratory Corporation of America Holdings

Report Scope

In this report, the Global Flow Cytometry in Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Flow Cytometry in Oncology Market, By Component

• Assays & Kits
• Instruments
• Reagents & Consumables
• Software

Flow Cytometry in Oncology Market, By Technology

• Cell Based
• Bead Based

Flow Cytometry in Oncology Market, By Indication

• Hematological Malignancies
• Solid Tumors

Flow Cytometry in Oncology Market, By Application

• Translational Research
• Clinical Applications

Flow Cytometry in Oncology Market, By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutions
• Others

Flow Cytometry in Oncology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Flow Cytometry in Oncology Market.

Available Customizations:

Global Flow Cytometry in Oncology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Assays & Kits, Instruments, Reagents & Consumables, Software)
  • 5.2.2. By Technology (Cell Based, Bead Based)
  • 5.2.3. By Indication (Hematological Malignancies, Solid Tumors)
  • 5.2.4. By Application (Translational Research, Clinical Applications)
  • 5.2.5. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Flow Cytometry in Oncology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Technology
  • 6.2.3. By Indication
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Flow Cytometry in Oncology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Flow Cytometry in Oncology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Flow Cytometry in Oncology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technology
  • 7.2.3. By Indication
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Flow Cytometry in Oncology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Flow Cytometry in Oncology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Flow Cytometry in Oncology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Flow Cytometry in Oncology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Flow Cytometry in Oncology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Flow Cytometry in Oncology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technology
  • 8.2.3. By Indication
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Flow Cytometry in Oncology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Flow Cytometry in Oncology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Flow Cytometry in Oncology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Flow Cytometry in Oncology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Flow Cytometry in Oncology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Flow Cytometry in Oncology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technology
  • 9.2.3. By Indication
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Flow Cytometry in Oncology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Flow Cytometry in Oncology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Flow Cytometry in Oncology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Flow Cytometry in Oncology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technology
  • 10.2.3. By Indication
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Flow Cytometry in Oncology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Flow Cytometry in Oncology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Flow Cytometry in Oncology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Flow Cytometry in Oncology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Apogee Flow Systems Ltd.
• 15.3. Becton, Dickinson and Company
• 15.4. bioAffinity Technologies, Inc.
• 15.5. Bio-Rad Laboratories, Inc.
• 15.6. Bio-Techne Corporation
• 15.7. Cytognos, S.L.
• 15.8. Danaher Corporation
• 15.9. Miltenyi Biotec B.V. & Co. KG
• 15.10. Laboratory Corporation of America Holdings

16. Strategic Recommendations

17. About Us & Disclaimer